COVID-19 Resources
-
25 February 2022
The Pharmaceutical Benefits Advisory Committee (PBAC) undertook an expedited consideration of a sponsor submission to add molnupiravir (Lagevrio®) to the Pharmaceutical Benefits Scheme (PBS) for use in treating patients with mild to moderate COVID-19 who are at risk of developing severe disease requiring hospitalisation. The expedited consideration by PBAC recognises the urgent public health need related to the prevention, management, or treatment of SARS-CoV-2 infections. The PBAC recommended the listing on the PBS of molnupiravir as a General Schedule, Authority Required (Streamlined) benefit. The outcome of the PBAC consideration is available on the PBS website.
-
Friday 18 February 2022, Online Webinar
PARTICIPANTS:
Australian medical oncology trainees, young clinicians, consultants and allied health professionals are invited to register at no cost to attend the webinar.
-
This position statement has been developed for cancer clinicians and other healthcare professionals caring for people with cancer. The COVID-19 pandemic is constantly evolving and the position statement may be updated with emergence of new evidence.
-
Guidance for cancer clinicians, focusing on areas in medical oncology affected by COVID19, including communication and the psychosocial impact of COVID19 on cancer patients, as well as tumour specific considerations.
-
As trainees we are building the foundations of a long-term career in Medical Oncology. This involves being trained in the science and the art of oncology. But it also involves setting good habits in place early, ensuring that we as carers of others’ health are noticing and managing our own as well. Please find below links to resources to hopefully aid in the development of both our knowledge and our overall wellbeing
-
Links to available international guidance regarding considerations for cancer management for cancer patients with COVID-19 are provided below. This may include cancer patients with both symptomatic and asymptomatic SARS-CoV-2 infection.
-
20 January 2022
Molnupiravir has provisional approval for the treatment of adults with COVID- 19 who do not require initiation of oxygen due to COVID and who are at increased risk of progression to severe COVID-19, including hospitalisation or death.
The decision to approve this indication was based on the analysis of efficacy and safety data from a Phase 3 trial. Continued approval of this indication depends on additional data.
Molnupiravir is an orally administered antiviral treatment that inhibits the replication of SARS-CoV-2, the causative agent of COVID-19. Molnupiravir has been investigated for the treatment of non- hospitalised adults, with mild-to-moderate laboratory-confirmed COVID-19, with at least one risk factor for severe illness.
1 Bernal AJ, et al. Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients | NEJM N Engl J Med DOI: 10.1056/NEJMoa2116044. 16 Dec 2021.
-
-
FAQs have been translated into the ten most commonly spoken languages in Australia other than English: available at www.canceraustralia.gov.au/CALD.
-